Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
18 participants
INTERVENTIONAL
2007-11-30
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma
NCT01897792
Oxidative Stress Links Aging, Activity, and Mobility Limitation
NCT01177189
Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients
NCT00133978
Effects of Plant Concentrate Blend on Oxidative Stress in Healthy Humans
NCT02213588
Impact Of Antioxidant Micronutrients On Intensive Care Unit (ICU) Outcome
NCT00515736
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
powdered antioxidant
one vial mixed with water every day orally or through enteral tube
2
powdered cornstarch placebo
one vial mix with water and administer orally or via enteral tube
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
powdered antioxidant
one vial mixed with water every day orally or through enteral tube
powdered cornstarch placebo
one vial mix with water and administer orally or via enteral tube
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Renal dysfunction (cre \> 2.5 mg/dl)
* Hepatic dysfunction ( TBili \> 3.0 mg/dl)
* Expected survival \< 48 hours
* Burns over \> 20% body surface area
* Immune-deficiency syndromes
* Steroid use
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boston Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Burke, MD
Role: STUDY_DIRECTOR
Boston Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-25038
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.